N/A N=109 What Makes People Better at Retrieving Proper Names?
Healthy Aging
Primary: Percent of Familiar Faces With TOT Responses — 16; 15; 18; 15 Percent of familiar faces with TOTs
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=34 Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
Sarcoma, Alveolar Soft Part
Primary: Part I: Objective Response Rate (ORR) of Single-agent Cediranib in Participants With Advanced Alveolar Soft Part Sarcoma (ASPS) — 0; 0; 0; 1 Participants
Phase 2 N=15 ERG/5-HTP in Fragile X Syndrome (FXS)
Fragile X Syndrome
Primary: Safety and Tolerability - Number of Treatment-Emergent Adverse Events — 2; 1; 1; 3 Number of Adverse Events
N/A N=46 The Water Drinking Test in Glaucoma Study
Glaucoma
Primary: Maximum Intraocular Pressure Difference (Between mDCT and WDT) — -0.82 mmHg
Phase 3 N=356 Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions Within 7 Days After Last Vaccination — 26.3; 29.7; 32.5; 13.2 Percentage of participants
Phase 3 N=356 A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia
Primary: Relapse-free Survival (RFS) — NA; NA months — p=0.0518
Phase 1 N=32 Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
HER2/Neu Negative · No Evidence of Disease · One or More Positive Axillary Nodes
Primary: Number of Adverse Events Per Common Terminology Criteria for Adverse Events Version 4.0 — 45; 53; 30; 2 Count of Related Adverse Events per Arm
Phase 4 N=63 Effect of Ketorolac on Post Adenotonsillectomy Pain
Obstructive Sleep Apnea
Primary: Post-Anesthesia Care Unit (PACU) Morphine Requirements — 0.033; 0.058 mg/kg
N/A N=355 Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC
Renal Cell Carcinoma (RCC)
Primary: Number of Participants With First Line Treatment Regimen — 340; 15 Participants
Phase 1 N=114 A Study Comparing the Pharmacokinetic Similarity of MB02-SP, MB02-DM and US Licensed-Avastin®.
Healthy Volunteers
Primary: Pharmacokinetics (PK) - (AUC[0-∞]) — 7500000; 8000000; 7520000 h*ng/ml
Phase 3 N=81 A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM
Obstructive Hypertrophic Cardiomyopathy
Primary: Change From Baseline to Week 30 in Valsalva Left Ventricular Outflow Tract (LVOT) Peak Gradient — -51.05; 19.23 mmHg
N/A N=167 Cognitive Training in Parkinson Study
Parkinson Disease · Impaired Cognition · Alteration in Cognition
Primary: Accuracy on the Tower of London Task — 81.2; 82.3; 88.1; 84.0 percentage of correct responses
Early Phase 1 N=44 Sensory Augmentation Methods in Stroke
Stroke
Primary: Percentage of Participants With Related or Serious Adverse Events — 1; 0 Participants — p=1
N/A N=320 Safety and Efficacy of the Oxford Cementless Partial Knee System
Osteoarthritis, Knee · Avascular Necrosis of the Medial Femoral Condyle
Primary: Radiographic Success — 198; 112; 13; 3 knees
N/A N=10 DISCOVER Workshop Programme for Care Experienced Young People
Mental Health Issue · Emotional Stress · Emotional Regulation
Primary: Participant Uptake (Feasibility & Acceptability) — 10 Participants